Related Experiment Video
Updated: Apr 15, 2026

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis
Published on: March 4, 2014
Minimal change multiple system atrophy: an aggressive variant?
Helen Ling1,2, Yasmine T Asi1, Igor N Petrovic2,3
1Queen Square Brain Bank, Department of Molecular Neuroscience, UCL Institute of Neurology, UK.
Background:
Glial cytoplasmic inclusions containing α-synuclein are the pathological hallmark of multiple system atrophy (MSA). Minimal change (MC-MSA) is an unusual MSA subtype with neuronal loss largely restricted to the substantia nigra and locus coeruleus.
Methods:
Immunohistochemistry on selected brain regions and semiquantitative assessment were performed on six MC-MSA and eight MSA control cases.
Results:
More neuronal cytoplasmic inclusions were seen in the caudate and substantia nigra in MC-MSA than in MSA controls (P = 0.002), without any statistical difference in glial cytoplasmic inclusion load in any region. Severe glial cytoplasmic inclusion load was found in the ventrolateral medulla (P = 1.0) and nucleus raphe obscurus (P = 0.4) in both groups. When compared with MSA controls, the three MC-MSA cases who had died of sudden unexpected death had an earlier age of onset (mean: 38 vs. 57.6 y, P = 0.02), a numerically shorter disease duration (mean: 5.3 vs. 8 y, P = 0.2) and a more rapid clinical progression with most of the clinical milestones reached within 3 y of presentation, suggesting an aggressive variant of MSA. Another three MC-MSA cases, who had died of unrelated concurrent diseases, had an age of onset (mean: 57.7 y) and temporal course similar to controls, had less severe neuronal loss and gliosis in the medial and dorsolateral substantia nigra subregions (P < 0.05) than in MSA controls, and could be considered as a unique group with interrupted pathological progression. Significant respiratory dysfunction and early orthostatic hypotension were observed in all MC-MSA cases.
Conclusions:
Our findings could suggest that α-synuclein-associated oligodendroglial pathology may lead to neuronal dysfunction sufficient to cause clinical symptoms before overt neuronal loss in MSA. © 2015 International Parkinson and Movement Disorder Society.
Insights
Minimal change multiple system atrophy (MC-MSA) shows more neuronal inclusions but similar glial pathology compared to typical MSA. Some MC-MSA cases exhibit aggressive disease progression and early symptoms before significant neuronal loss.
Area of Science:
- Neuroscience
- Neuropathology
- Movement Disorders
Background:
- Multiple system atrophy (MSA) is characterized by glial cytoplasmic inclusions (GCIs) containing alpha-synuclein.
- Minimal change MSA (MC-MSA) is a rare subtype with neuronal loss primarily in the substantia nigra and locus coeruleus.
Purpose of the Study:
- To investigate the neuropathological differences between MC-MSA and typical MSA.
- To characterize the clinical and pathological progression in MC-MSA.
Main Methods:
- Immunohistochemistry and semiquantitative assessment of brain regions from six MC-MSA and eight MSA control cases.
- Comparison of neuronal cytoplasmic inclusions (NCIs) and GCIs load between groups.
Main Results:
- MC-MSA cases showed significantly more NCIs in the caudate and substantia nigra compared to MSA controls.
- No significant difference in GCI load was observed between MC-MSA and MSA controls in any region.
- MC-MSA cases with sudden unexpected death presented with earlier onset and rapid progression, suggesting an aggressive variant. Other MC-MSA cases showed interrupted pathological progression.
- Significant respiratory dysfunction and early orthostatic hypotension were present in all MC-MSA cases.
Conclusions:
- Alpha-synuclein-associated oligodendroglial pathology in MSA may cause neuronal dysfunction preceding overt neuronal loss.
- MC-MSA represents a distinct clinicopathological entity within the spectrum of MSA.
Related Concept Videos
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Parkinson's Disease: Overview

